IL6 and autoimmune disease: Furthermore, the interplay between IFNβ and IL-6 is likely to be affected in the context of the use of jakinibs, small-molecule therapeutics for autoimmune disease that inhibit the activity of one or more of the Janus kinase (JAK) enzymes to shape the STAT signaling in immune cells (50, 51).